BR112018074027A2 - tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo - Google Patents
tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmoInfo
- Publication number
- BR112018074027A2 BR112018074027A2 BR112018074027-6A BR112018074027A BR112018074027A2 BR 112018074027 A2 BR112018074027 A2 BR 112018074027A2 BR 112018074027 A BR112018074027 A BR 112018074027A BR 112018074027 A2 BR112018074027 A2 BR 112018074027A2
- Authority
- BR
- Brazil
- Prior art keywords
- thiophene
- manufacture
- pharmaceutical
- pharmaceutical application
- treating
- Prior art date
Links
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title abstract 6
- 229930192474 thiophene Natural products 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 2
- 229940116269 uric acid Drugs 0.000 abstract 2
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010018634 Gouty Arthritis Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
a presente invenção descreve um tiofeno usado como um inibidor do transportador de ácido úrico (urat1) e aplicação do tiofeno na preparação de um produto farmacêutico para tratar uma doença relacionada a níveis de ácido úrico anormais, especificamente na preparação de um produto farmacêutico para tratar a hiperuricemia e artrite gotosa. a invenção especificamente refere-se a um composto como representado por fórmula (i) ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610343321 | 2016-05-23 | ||
| CN201610343321.0 | 2016-05-23 | ||
| PCT/CN2017/085458 WO2017202291A1 (zh) | 2016-05-23 | 2017-05-23 | 噻吩化合物及其合成方法和其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018074027A2 true BR112018074027A2 (pt) | 2019-02-26 |
Family
ID=60411095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074027-6A BR112018074027A2 (pt) | 2016-05-23 | 2017-05-23 | tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10829483B2 (pt) |
| EP (1) | EP3466946B1 (pt) |
| JP (1) | JP6724246B2 (pt) |
| KR (1) | KR102244216B1 (pt) |
| CN (1) | CN109790155B (pt) |
| AU (1) | AU2017270858B2 (pt) |
| BR (1) | BR112018074027A2 (pt) |
| CA (1) | CA3025078C (pt) |
| ES (1) | ES2961901T3 (pt) |
| MX (1) | MX2018014374A (pt) |
| NZ (1) | NZ749427A (pt) |
| RU (1) | RU2709473C9 (pt) |
| WO (1) | WO2017202291A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972065A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
| KR102246619B1 (ko) * | 2017-11-23 | 2021-04-30 | 메드샤인 디스커버리 아이엔씨. | Urat1 억제제의 결정형 및 그의 제조 방법 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| MX2022004713A (es) * | 2019-10-30 | 2022-05-11 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos. |
| CR20220294A (es) | 2019-12-20 | 2022-08-03 | Bayer Ag | Tiofenocarboxamidas sustituidas y sus derivados |
| CN113368067A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 制备用于降低血液尿酸水平的口服药物片剂的方法 |
| CN113368032A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 药物组合物、口服固体制剂及其制备方法和用途 |
| CN113368073A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 制备用于降低血液尿酸水平的药物制剂的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2133332T3 (da) * | 2007-04-11 | 2013-09-30 | Kissei Pharmaceutical | (aza)indolderivat og anvendelse deraf til medicinske formål |
| EP2842948A1 (en) * | 2007-11-27 | 2015-03-04 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
| MX2011002449A (es) * | 2008-09-04 | 2011-05-25 | Ardea Biosciences Inc | Compuestos, composiciones y métodos para utilizar los mismos para modular niveles de ácido úrico. |
| CN106176736A (zh) * | 2010-10-15 | 2016-12-07 | 阿迪亚生命科学公司 | 用于治疗高尿酸血症及相关疾病的方法 |
| UA117359C2 (uk) * | 2012-11-14 | 2018-07-25 | Тейдзін Фарма Лімітед | Похідне піридину |
| EP3275867B1 (en) * | 2015-03-24 | 2020-06-10 | Shanghai Yingli Pharmaceutical Co. Ltd. | Pyrido-fused bicyclic compounds as urat1 inhibitors for treating hyperuricemia |
| CN105399694B (zh) | 2015-12-11 | 2017-09-15 | 浙江京新药业股份有限公司 | 药物Lesinurad轴手性对映体 |
-
2017
- 2017-05-23 EP EP17802137.4A patent/EP3466946B1/en active Active
- 2017-05-23 US US16/303,767 patent/US10829483B2/en active Active
- 2017-05-23 CA CA3025078A patent/CA3025078C/en active Active
- 2017-05-23 WO PCT/CN2017/085458 patent/WO2017202291A1/zh unknown
- 2017-05-23 RU RU2018144818A patent/RU2709473C9/ru active
- 2017-05-23 MX MX2018014374A patent/MX2018014374A/es unknown
- 2017-05-23 AU AU2017270858A patent/AU2017270858B2/en active Active
- 2017-05-23 JP JP2019514169A patent/JP6724246B2/ja active Active
- 2017-05-23 KR KR1020187037287A patent/KR102244216B1/ko active IP Right Grant
- 2017-05-23 CN CN201780031676.9A patent/CN109790155B/zh active Active
- 2017-05-23 NZ NZ74942717A patent/NZ749427A/en unknown
- 2017-05-23 BR BR112018074027-6A patent/BR112018074027A2/pt active Search and Examination
- 2017-05-23 ES ES17802137T patent/ES2961901T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3466946A4 (en) | 2019-11-06 |
| JP2019519606A (ja) | 2019-07-11 |
| EP3466946B1 (en) | 2023-08-30 |
| NZ749427A (en) | 2019-11-29 |
| CN109790155B (zh) | 2022-02-18 |
| CA3025078C (en) | 2021-04-13 |
| KR102244216B1 (ko) | 2021-04-26 |
| US20200140423A1 (en) | 2020-05-07 |
| AU2017270858A1 (en) | 2019-01-17 |
| RU2709473C1 (ru) | 2019-12-18 |
| WO2017202291A1 (zh) | 2017-11-30 |
| RU2709473C9 (ru) | 2020-06-16 |
| KR20190009377A (ko) | 2019-01-28 |
| JP6724246B2 (ja) | 2020-07-15 |
| US10829483B2 (en) | 2020-11-10 |
| EP3466946A1 (en) | 2019-04-10 |
| ES2961901T3 (es) | 2024-03-14 |
| CA3025078A1 (en) | 2017-11-30 |
| AU2017270858B2 (en) | 2019-09-19 |
| CN109790155A (zh) | 2019-05-21 |
| MX2018014374A (es) | 2019-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018074027A2 (pt) | tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| BR112013024171A2 (pt) | método para o tratamento e prevenção de uma condição neurodegenerativa | |
| BR112018015474A2 (pt) | agonista de fxr derivado de esteroide | |
| BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| CL2017002179A1 (es) | Sales de inhibidor de pi3k y procesos de preparación | |
| PH12017501160A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
| BR112016024571A2 (pt) | composto de 1,2,4-triazina dissubstituído | |
| CY1120515T1 (el) | Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EA201692037A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| MY195675A (en) | A Group of Compounds used for the Treatment or Prevention of Hyperuricemia or Gout | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) ; CSTONE PHARMACEUTICALS (KY) ; MEDSHINE DISCOVERY INC. (CN) |
|
| B25A | Requested transfer of rights approved |
Owner name: CSTONE PHARMACEUTICALS (KY) ; MEDSHINE DISCOVERY INC. (CN) ; MEDSHINE DISCOVERY INC. (CN) |
|
| B25A | Requested transfer of rights approved |
Owner name: MEDSHINE DISCOVERY INC. (CN) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |